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Abstract
Background: Invasive group B Streptococcus (GBS) disease in Chinese infants has gradually gained attention in
recent years, but the molecular epidemiology of the pathogen is still not well known.
Methods: This multicenter study retrospectively investigated distribution of capsular serotypes, sequence types
(STs), and hypervirulent GBS adhesin gene (hvgA) in clinical GBS isolates that caused invasive disease in infants aged
< 3 months of age in southern mainland China between January 2013 and June 2016. Genes for antibiotic
resistance to tetracycline, erythromycin, and clindamycin were also examined.
Results: From a total of 93 GBS isolates taken from 34 early-onset disease (EOD, 0–6 days after birth) and 59 late-
onset disease (LOD, 7–89 days after birth) cases, four serotypes were identified: serotypes III (79.6%), Ib (12.9%), Ia
(4.3%), and V (3.2%). Serotype III accounted for 73.5% of EOD and 83.1% of LOD and was responsible for 75.5% of
cases involving meningitis. Fifteen STs were found, with the majority being ST17 (61.3%), ST12 (7.5%), ST19 (7.5%),
and others (23.7%). 96.8% of STs belonged to only five clonal complexes (CCs): CC17 (64.5%), CC10 (12.9%), CC19
(9.7%), CC23 (6.5%), and CC1 (3.2%). The hvgA gene was detected in 66.7% of GBS isolates and 95% of CC17
isolates, all of which were serotype III except one serotype Ib/CC17 isolate. A large proportion of GBS isolates were
found to be resistant to tetracycline (93.5%), clindamycin (65.5%), and erythromycin (60.2%). Genes of tetO (74.7%)
and tetM (46.0%) were found in tetracycline resistant isolates, linB (24.6%) in clindamycin resistant isolates, and ermB
(87.5%) and mefA (3.6%) in erythromycin resistant isolates.
Conclusion: Our results reveal higher prevalence of serotype III, ST17, CC17, hvgA expressing, and antibiotic
resistant GBS isolates than previously reported in southern mainland China.
This study provides guidance for appropriate measures of prevention and control to be taken in the future.
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Background
Group B Streptococcus (GBS), also called Streptococcus
agalactiae, is a main causative pathogen of invasive neo-
natal bacterial infection, causing high morbidity and
mortality [1–3]. A meta-analysis by Madrid et al. found
that the incidence of invasive GBS disease in infants
worldwide was 0.49 per 1000 live births (95% confidence
interval [CI], 0.43–0.56), and was highest in Africa (1.12)
and lowest in Asia (0.30) [4]. Some potential factors
which may contribute to the apparent lower incidence in
Asia include the low overall prevalence of maternal
colonization, incomplete case ascertainment, and the
lack of well-trained clinicians and appropriate laboratory
facilities to identify the disease, especially in primary
healthcare centers [5]. In this meta-analysis, early-onset
disease (EOD) and late-onset disease (LOD) were de-
fined as invasive GBS infections occurring 0–6 days and
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7–89 days after birth, respectively [6]. GBS is a highly di-
verse organism and commonly colonizes the human
gastrointestinal and genitourinary tracts. Based on cap-
sular polysaccharides (CPS), GBS can be classified into
10 serotypes including Ia, Ib, and II through IX. How-
ever, only limited subtypes have been identified in in-
fants with invasive infection, indicating that variation in
expressed surface molecules is related to pathogenicity
of strains. The Madrid et al. meta-analysis found that
serotype III accounted for the highest proportion of se-
rotypes globally (61.5%) [4], while our group’s recent
study found the proportion of serotype III in Guangdong
province was 77.9% [7], much higher than the global
level. Jones et al. analyzed GBS isolates with multilocus
sequence typing (MLST) and reported that serotype III
strains have been categorized to ST17 and belong to
complex clone 17 (CC17) [8]. In the CC17 lineage,
which is strongly associated with neonatal meningitis,
the hvgA gene encoding a surface-anchored protein
named hypervirulent GBS adhesin (HvgA) has been
identified [9]. The HvgA surface-anchored protein not
only acts as an important adhesion medium for destroy-
ing and penetrating the intestinal and blood-brain bar-
riers, but also mediates the migration of bacteria into
the bloodstream and the central nervous system, which
leads to infection [9, 10].
In addition to expressing many factors which help it
evade immune detection and clearance, acquiring anti-
microbial resistance genes is another strategy observed
in GBS to improve survival within the host. Penicillin G
and ampicillin are recommended by U.S. CDC as the
first-line drugs for prophylaxis and treatment of neo-
natal GBS infection, while clindamycin was the recom-
mended alternative for individuals with a β-lactam
allergy [6, 11]. Unfortunately, the proportion of isolates
reported to be resistant to erythromycin and clindamy-
cin has increased in recent years, and especially high
macrolide resistance in GBS have been detected among
isolates circulating in both infected infants and adult fe-
male carriers in China [11–13].
Although invasive GBS infection in Chinese infants
has gradually gained attention in recent years, no stan-
dardized or official guidelines for GBS prevention and
control exists and the molecular epidemiology of the
pathogen remains not well known. Furthermore, pub-
lished studies have shown that geographical and ethnic
differences in hosts effect the molecular epidemiology of
invasive GBS [9, 14–17]. By determining serotypes, se-
quence types (STs), hvgA expression and antibiotic re-
sistance of GBS isolates from infants with invasive
infections in four hospitals in Guangdong province,
China between January 1, 2013 and June 30, 2016, this
study aims to elucidate the molecular characteristics of
neonatal GBS disease prevailing in southern mainland
China. This work will be helpful for exploring preventive
and treatment strategies for GBS infections in southern
mainland China and for the development of serotype-
based vaccines in the future.
Methods
Study design
The study population was comprised of infants younger
than 90 days of age with GBS isolated from a normally
sterile medium including blood, cerebrospinal fluid
(CSF), synovial fluid, and/or bone marrow, from the fol-
lowing four hospitals in Guangdong, China, between
January 1, 2013 and June 30, 2016: Guangzhou Women
and Children’s Medical Center, Dongguan Tungwah
Hospital, Guangdong Women and Children’s Hospital,
and Zhongshan Boai Hospital. We retrospectively col-
lected demographic information, clinical signs and
symptoms, and laboratory data for each GBS patient
from Hospital Information Systems (HIS) and medical
records at each study site.
GBS sepsis was defined as neonates in whom GBS was
cultured from blood with clinical symptoms or signs in-
cluding fever, respiratory distress, apnea, cyanosis, poor
feeding, jaundice, lethargy, and seizure. Additionally,
meningitis was diagnosed if a) CSF was cultured positive
for GBS, or b) GBS negative but with a cellular reaction
of more than 20 leukocytes/μL in CSF associated with
GBS positive blood culture and consistent clinical
manifestation.
GBS isolates
All GBS strains were confirmed by the four study hospi-
tals to be S. agalactiae using VITEK 2 COMPACT
microbiology systems (BioMerieux, Marcy L’Etoile,
France). GBS isolates collected during the study period
were centralized in the microbiology laboratory of
Guangzhou Women and Children’s Medical Center for
analysis, where they were cultured at 37 °C in 5% CO2 in
trypticase soy agar supplemented with 5% sheep blood.
We used ATCC 2592 and ATCC 49619 as quality con-
trol bacteria.
Capsular serotyping
GBS serotyping was performed using Strep-B-Latex®
rapid latex agglutination test kit (Statens Serum Insti-
tute, Hillerød, Denmark), according to the manufac-
turer’s instructions. The capsular genotype was verified
using a previously described multiplex PCR assay [18].
Multilocus sequence typing (MLST)
Genomic DNA was prepared from overnight GBS cul-
tures by a standard protocol for Gram-Positive bacteria,
using Bacterial Genomic DNA kit (Takara Code
NO.9164, Japan). Typing was performed by sequencing
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the internal fragments of seven house-keeping genes
(adhP, pheS, atr, glnA, sdhA, glcK, and tkt). PCR was
used to amplify genomic DNA using the primer pairs in-
dicated at http://pubmlst.org/sagalactiae/info/primers.
shtml. PCR products were purified and sequenced in
both directions by BGI Tech Solutions Co. Ltd. Alleles
and sequence types (STs) were determined using the S.
agalactiae MLST website (http://pubmlst.org/sagalac-
tiae/). Sequence types that shared five or more alleles of
the seven loci were clustered into a clonal complex (CC)
using eBURST software. The term “singleton ST” refers
to an ST that did not cluster into a CC. BioNumerics
software version 5.1 (Applied Maths, Belgium) was used
to create minimum spanning trees to illustrate relation-
ships between MLST and CCs.
Detection of hypervirulent GBS adhesion (hvgA) gene
The hvgA gene was amplified by PCR using previously
described primers ST17S and ST17AS [18]. Amplifica-
tion products were purified and sequenced by BGI Tech
Solutions Co. Ltd.
Antibiotic resistance
We used VITEK 2 COMPACT microbiology systems to
determine the minimum inhibitory concentrations
(MICs) of the following 11 antibiotics: penicillin, ampi-
cillin, ceftriaxone, vancomycin, linezolid, erythromycin,
azithromycin, levofloxacin, ofloxacin, ciprofloxacin and
clindamycin. The criteria of the Clinical and Laboratory
Standards Institute (CLSI), 2016 edition, were applied
for interpretation. S. pneumonia ATCC 49619 and
Staphylococcus aureus ATCC25923 were used as quality
control strains in each set of tests to ensure accuracy of
results. Erythromycin resistant genes erm(A), erm(B),
mef(A), and tetracycline resistant genes tet(L), tet(K),
tet(O), tet(m), being the most common antimicrobial
genes, were detected by PCR. The primers and PCR con-
ditions followed previously described methods [19, 20].
Statistical analysis
Continuous data was expressed in terms of numbers and
percentages and Fisher’s exact test was used for
comparison of categorical variables. Statistical analyses
were performed using SPSS software (ver. 21.0; SPSS
Inc., U.S). A p-value of < 0.05 was considered statistically
significant. All antibiotic susceptibility data were ex-
tracted using WHONET 5.6 software, as recommended
by the World Health Organization (WHO).
Results
A total of 93 non-duplicate GBS isolates which caused
invasive disease in infants were recovered; among them
were 65 from Guangzhou Women and Children’s Med-
ical Center, 12 from Dongguan Tungwah Hospital, 8
from Guangdong Women and Children’s Hospital and
Health Institute, and 8 from Zhongshan Boai Hospital.
GBS identification by the Vitken Compact 2 system were
confirmed for all isolates using mass spectrometry. A
total of 34 cases (36.6%) were diagnosed as EOD and 59
(63.4%) were diagnosed as LOD (Table 1). There were
49 GBS cases which were diagnosed with meningitis,
47% (16/34) of which were observed in EOD cases and
55.9% (33/59) in LOD cases. Overall, there were 43 GBS
cases which were diagnosed with sepsis, and one case
with arthritis.
Serotype distribution
Four capsular types were identified among the 93 iso-
lates. Serotype III was the most prevalent (74, 79.6%),
followed by Ib (12, 12.9%), Ia (4, 4.3%) and V (3, 3.2%).
Serotype III was also the most prevalent serotype of both
EOD (73.5%, 25/34) and LOD (83.1%, 49 /59) cases
(Fig. 1). Among the 49 cases with meningitis, serotype
III accounted for 62.5% (10/16) and 81.8% (27/33) in
EOD and LOD cases, respectively. There was no differ-
ence in distribution of serotype III between the meningi-
tis group (37/49) and non-meningitis group (37/44, P =
0.440).
Multilocus sequence typing
MLST analysis revealed the presence of 15 separate STs
among the 93 invasive GBS isolates. The relationships
between the STs, CCs, and serotypes of the 93 invasive
GBS strains are presented in Table 2. The most frequent
Table 1 Clinical information of GBS strains by isolate source and disease onset
Culture source Early-onset disease
(n = 34)
Late-onset disease
(n = 59)
Total
(n = 93)
Blood, n (%) 28 (82.4) 34 (57.6) 62 (66.7)
Cerebrospinal fluid, n (%) 1 (2.9) 16 (27.1) 17 (18.3)
Cerebrospinal fluid+blood, n (%) 5 (14.7) 8 (13.6) 13 (14.0)
Articular cavity fluid, n (%) 0 1 (1.7) 1 (1.1)
Bacteremia, n (%) 18 (53.0) 25 (42.4) 43(46.2)
Meningitis, n (%) 16 (47.0) 33 (55.9) 49(52.7)
Septic arthritis, n (%) 0 1 (1.7) 1(1.1)
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ST was ST17 (57, 61.3%), followed by ST12 (7, 7.5%),
ST19 (7, 7.5%), and ST23 (4, 4.3%).
Fourteen of the STs were clustered into five CCs (1,
10, 17, 19, and 23), and one ST651 was a singleton.
Among the 93 isolates, 90 (96.8%) were found within
five CCs: CC17 (64.5%), CC10 (12.9%), CC19 (9.7%),
CC23 (6.5%), and CC1 (3.2%). Of all isolates, 3 (3.2%)
were identified as singleton ST651 (Fig. 2). The serotype
and MLST analyses showed that isolates of the same CC
usually expressed one dominant serotype, indicating a
relationship between CCs and serotypes. Of the 74 sero-
type III strains, 2 major CCs were detected, where 58
(78.4%) strains belonged to CC17 and 9 (12.2%)
belonged to CC19. Serotype Ia clustered in CC23 and
serotype V in CC1, while Ib strains clustered into CC10
(75.0%), CC17 (16.7%), and CC23 (8.3%). Sepsis observed in 10 (55.6%) EOD cases and 18 (69.2%) LOD cases
were caused by CC17, while meningitis in 9 (56.3%)
EOD cases and 23 (69.7%) LOD cases were caused by
CC17. Invasive serotype III strains were significantly
associated with ST17 and CC17 (p < 0.001). CC17
was not only detected as serotype III (57 of strain
ST17 and 1 of strain ST188), but also found as sero-
type Ib/ST357 (2 strains).
Hypervirulent GBS adhesion gene
The hvgA gene was detected in 66.7% of the invasive
GBS isolates (62/93, Table 2), and 95% of CC17 isolates
(57 of 60) carried the hvgA gene. Additionally, the hvgA
gene was also found in CC10 (3), CC19 (1), and CC23
(1). All hvgA genes were detected in the serotype III iso-
lates (61 of 74 serotype III isolates, 82.4%), except one
serotype Ib/CC17 isolate. The isolates carrying hvgA
caused infections mainly manifesting as meningitis (32,
65.3%) and sepsis (30, 68.2%).
Fig. 1 Serotype distribution of GBS isolates from early-onset disease
and late-onset disease cases of GBS. The percentage of serotype III
was the highest among four serotypes, both in EOD and LOD. GBS,
group B streptococcus; EOD, early-onset disease; LOD,
late-onset disease
Table 2 Distribution of sequence types and hvgA gene in GBS
isolates across serotype
Serotype (n) CC (ST, n) CC17 (n) hvgA+ (n)
Ia (4) CC23 (ST23, 3; ST24, 1) – –
Ib (12) CC10 (ST10, 1; ST12, 7; ST579, 1) – –
CC17 (ST357, 2) 2 1
CC23 (ST23, 1) – –
III (74) CC17 (ST17, 57; ST188, 1) 58 56
CC19 (ST19, 7; ST27, 2) – 1
CC10 (ST562, 1; ST399, 2) – 3
CC23 (ST55, 1) – 1
ST651 (3)a – –
V (3) CC1 (ST1, 3) – –
Total (93) 60 (64.5%) 62 (66.7%)
CC clonal complex, ST sequence type, hvgA hypervirulent GBS adhesion gene
aST651 was a singleton
Fig. 2 Correlation between clone complexes (CCs), sequence type
(ST) and serotypes of invasive group B Streptococcus isolates. In the
minimum spanning tree, the STs are displayed as circles. The size of
each circle indicates the number of isolates of that particular ST,
with each colour represents a different serotype. The founder ST was
defined as the ST with the greatest number of single-locus variants.
The major clonal complexes (CCs) are indicated in the diagram. The
colours of the halo surrounding the STs denote types that belong to
the same CC. STs that vary by one allele in their multilocus
sequence typing profiles (single locus variants) are arranged in
circles around the primary founder sequence type. The numbers on
the lines represent the number of locus variants. ST17 was the most
frequent ST among 15 STs identified. Most of GBS isolates were
found within five clonal complexes (CCs): CC17, CC10, CC19, CC23,
and CC1, with CC17 being the most common
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Antimicrobial resistance phenotypes and genotypes
Universal antimicrobial susceptibility to β-lactam antibi-
otics (penicillin and ampicillin) was detected, while low
levels of resistances were observed for levofloxacin
(8.6%), ofloxacin (2.2%), and azithromycin (1.1%). 93.5%
of isolates (87) were resistant to tetracycline, owing to
the tetO gene in 74.7% (65/87) and tetM gene in 46.0%
(40/87) of GBS isolates, while the tetL and tetK genes
were not observed (Table 3). Moreover, both tetO and
tetM genes were detected in 2 of the 6 tetracycline-sus-
ceptible isolates. Erythromycin resistance (60.2%) was
mostly due to modifications of the ribosomes, linked to
the presence of ermB (87.5%, 48 isolates), and in 3.6% (2
isolates) of cases to an efflux mechanism encoded by the
genetic determinant mefA. The ermA gene was not
found, but ermB was detected in 30.0% (6/20) of
erythromycin-susceptible isolates. Resistance to clinda-
mycin was observed in 61 isolates (65.6%) and there
were another 12 isolates (12.9%) exhibiting erythro-
mycin-induced clindamycin resistance. The linB gene
was identified in 24.6% (15/61) of clindamycin-resistant
isolates. The resistance to tetracycline, erythromycin,
and clindamycin was not significantly different between
serotypes or CC17 isolates, but resistance to clindamycin
was higher in GBS isolates with hvgA than the isolates
without (p < 0.05).
Discussion
GBS remains a leading cause of infant sepsis and menin-
gitis worldwide within the first 90 days of life. The recent
meta-analysis by Madrid et al. showed the incidence of
invasive GBS disease in infants was 0.49 per 1000 live
births worldwide, with serotype III (61.5%) being the
dominant type and with 97% of cases caused by just five
serotypes (Ia, Ib, II, III, and V) [4]. In the present study,
serotypes Ia, Ib, III, and V were detected, and serotype
III was the dominant serotype observed (79.6%), which
is higher than the global average of 61.5% cited above,
but similar to estimates from France [9], Italy [20] and
other parts of China [7, 13].GBS vaccines covering five
serotypes (Ia, Ib, II, III and V) have already entered
Phase III clinical trials [16]; an approved vaccine would
cover 95% of global newborn GBS infection [2, 5, 21],
and would protect from all serotypes detected in this
study. Additionally, in contrast to the approximately
50% of GBS-related meningitis cases caused by serotype
III in infants worldwide [21, 22], serotype III accounted
for 62.5 and 81.8% in EOD and LOD cases with menin-
gitis in this study group, respectively.
In the present study, we obtained 15 STs from 93 in-
vasive GBS isolates, of which 61.3% were caused by the
highly pathogenic genotype ST17. The five types of CCs
detected in this study (CC17, CC1, CC10, CC19, and
CC23) are also the most common clones globally.
Among 93 isolates, more than half of neonatal GBS in-
fection were caused by the highly pathogenic strain
CC17 (ST17, ST357, ST188). We found serotype III was
more commonly associated with the most virulent clone,
clonal complex (CC17). CC17 accounted for 78.4% of
serotype III strains, and mainly caused the observed
meningitis. Studies have shown that less than 12% of
GBS strains with ST17 colonize adults, whereas CC17,
in contrast, presents as highly pathogenic and virulent
among both infants with under-developing immune sys-
tems and immunocompromised patients [10]. In the
process of occurrence and development of neonatal in-
vasive infection, CC17 strains enhance the pathogenicity
and invasiveness of GBS through a special virulence
mechanism, which is the main cause of meningitis in
these patients (> 80%) [9, 10, 23, 24]. CC17 colonization
is the main risk factor for neonatal GBS infection [25,
26]. A study from the Netherlands found that the main
contributing factor to the increase in incidence of GBS
infection between 1987 and 2011 was the increase in
prevalence of CC17 [25]. Manning SD et al. [23] found
ST17 and ST19 were the local dominating genotypes of
neonatal invasive infections in Canada, and that ST1,
ST12, and ST23 were the primary genotypes among
pregnant women. In China, similar to the results of that
study, ST17 was found as the main genotype for new-
borns infected with GBS, and ST19 for pregnant women
[27]. CC17 and CC19 are the most common important
gene pedigrees of GBS serotype III, and likely for that
reason serotype III is the most common serotype caus-
ing GBS invasive disease in infants.
Our findings showed around 95% of serotype-III/CC17
isolates harbouring the hvgA gene, which suggested that
hvgA is involved in the pathogenesis of invasive GBS
Table 3 Comparison of resistance to tetracycline, erythromycin, and clindamycin of GBS isolates with different serotypes, CC17 and
hvgA
Total
(n = 93)
Serotypes (n,%) CCs (n,%) hvgA (n,%)
Ia (n = 4) Ib (n = 12) III (n = 74) IV (n = 3) CC17 (n = 60) Non-CC17
(n = 33)
hvgA(+)
(n = 62)
hvgA(−)
(n = 31)
Tetracycline 87 (93.5%) 4 (100%) 11 (91.7%) 69 (93.2%) 3 (100%) 57 (95.0%) 30 (90.9%) 60 (96.8%) 27 (87.1%)
Erythromycin 56 (60.2%) 2 (50%) 7 (58.3%) 45 (60.8%) 2 (66.7%) 38 (63.3%) 18 (54.5%) 39 (62.9%) 17 (54.8%)
Clindamycin 61 (65.6%) 1 (25%) 8 (66.7%) 50 (67.6%) 2 (66.7%) 40 (66.7%) 21 (63.6%) 46 (74.2%)a 15 (48.4%)
aCompared to the hvgA(+) isolates, P < 0.05
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infectious diseases. The ST17 strain without the selective
hvgA gene presents low adhesion to the host cell, which
is comparable to that of the non-ST17 strain [10]. The
hvgA gene was previously known to be carried only by
ST17, while our study found the hvgA gene was mainly
detected from strains with CC17 (92%,57/62), while
CC10, CC19, and CC23 strains also carried the hvgA
gene. Moreover, a strain with serotype-Ib/ST357/CC17
had the hvgA gene as well. Our findings also indicated
that most of the hvgA genes have been detected in sero-
type-III/ST17 strains, which is consistent with other re-
ported findings [18, 28].
Antimicrobial susceptibility testing of GBS isolates is
critical for selecting appropriate antibiotic treatment. We
found all isolates were susceptible to β-lactam antibiotics
over the study period. Some studies have found that there
was a decrease in the susceptibility of GBS to β-lactam
(such as penicillin and cephalosporin) [29–31]. This study
found that 93.5% of GBS isolates showed resistance to
tetracycline, comparable to France (90, 95.5%) [24, 26],
Italy (93.3%) [20], and Beijing (100%) [13]. The rate of
erythromycin resistance was 60.2%, which is higher than
previous results from France (16.7, 13.8%) [24, 26], Italy
(12%) [20], and the United States (32%) [2]. This high re-
sistance to macrolide antibiotics including erythromycin
and clindamycin is possibly due to the overuse of antibi-
otics in animal husbandry and humans in China in the
past decades. We found 85.7% of the erythromycin-resist-
ant strains carried the resistance gene ermB. In this study,
tetracycline resistance was mainly mediated by tetO and
tetM, with carrier gene rates of 75 and 46%, respectively,
whereas European countries were mainly dominated by
tetM, with gene rates of 95% in France [24, 26] and 97.1%
in Italy [20]. Furthermore, it was observed that a small
number of antibiotic-sensitive GBS strains carried resist-
ant genes, such as tetracycline-sensitive strains and
erythromycin-sensitive strains. We also found linB is an
important reason for clindamycin resistance; among 61
strains of clindamycin-resistant strains, 15 (24.6%) strains
had the linB gene. This is lower than observations in
South Africa where 38% (11/29) of strains had linB [32].
In contrast, linB was not detected in some investigations
from Korean [33] and Iran [34]. Our group’s previous
work revealed multi-drug resistance clusters (tetracycline,
aminoglycoside, macrolide/lincomycin, and others) in
GBS CC17 hypervirulent isolates by using genomic ana-
lysis [35]. This suggests that the antibiotics recommended
by the intrapartum antibiotic prophylaxis program to pre-
vent neonatal GBS in southern China are in need of up-
dating. On the other hand, in addition to strengthening
the rational use of antibiotics, and taking into account the
higher proportion of CC17 of neonatal infection at the
local level, we suggest more attention should be put on
GBS multi-drug resistance control.
Until now, many studies have reported on the resist-
ance spectrum of GBS strains among colonized pregnant
women, but by contrast, fewer studies have been per-
formed on the resistance spectrum of neonatal GBS in-
fection [2, 13, 20, 24, 26]. In this study, genotypes
exhibiting resistance to tetracycline and erythromycin
were significantly correlated with a drug-resistant
phenotype. However, antibiotic resistance was not lim-
ited to a specific serotype or sequence type. There was
no correlation between GBS resistance and serotype,
gene sequence type, and type of disease presentation. A
study by Poyart C. et al. demonstrated similar results
[24], but other studies have found the opposite. Joubrel,
C. et al. reported that GBS serotype had a correlation
with resistance, with the serotype-III strain having a low
resistance rate and a high resistance rate to serotype-V
strain [26]. One possible reason might be due to differ-
ences in the study population.
Our study has several limitations. GBS isolates were
only from one province in China, Guangdong, and the
sample size is relatively small. Therefore, these findings
may not uniformly represent the whole China. We also
did not collect data of population-based incidence rate
and maternal information, which prevented limited fur-
ther population-level analysis.
Conclusions
The molecular epidemiologic characteristics of GBS neo-
natal invasive infections in southern China were mainly
comprised of serotype-III/CC17. In Guangdong, resist-
ance to tetracycline was mainly associated with tetO and
tetM genes, erythromycin resistance was associated with
the presence of ermB, and clindamycin resistance was
associated with linB. It is recommended to establish cor-
responding prevention and control measures accord-
ingly. Further large scale studies and routine GBS
surveillance are required to learn more about this infec-
tion and to prevent it from occurring.
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